Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for October 2011
October 3, 2011
- EntreMed's ENMD-2076 Demonstrates Promising Activity in a Phase 2 Study in Platinum-Resistant Ovarian Cancer Patients
- Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints
- Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin
- In Reversing Motor Nerve Damage, Time Is of the Essence
- Biovest to Present on Regulatory Strategy for BiovaxID Cancer Vaccine at MD Becker Cancer Immunotherapy Conference
- Kineta Scientists to Present Novel Antiviral Research Findings at International Conference
- Vertex Announces Presentation of New Data on VX-770 and VX-809 at North American Cystic Fibrosis Conference
October 4, 2011
- NOVAVAX Reports Positive Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate
- InSite Vision Announces Positive Phase 2 PK Results for BromSite (ISV-303) for the Reduction of Pain and Inflammation After Cataract Surgery
October 5, 2011
- Forest Laboratories, Inc. and Gedeon Richter Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
- BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to Allopurinol Alone
- Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
- Sunshine Biopharma's anti-cancer compound, Adva-27a, found to be a strong Topoisomerase II inhibitor
- Aeterna Zentaris: Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of Perifosine Plus Capecitabine in Patients with Metastatic Colorectal Cancer
- New FDA Study Finds No Developmental Effects from BPA
October 6, 2011
- Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
- Voclosporin Study Published in the American Journal of Transplantation
October 7, 2011
- Dynavax Reports Diabetic Subset Data From Modified Intent to Treat Analysis of the HEPLISAV Phase 3 Trial in Healthy Adults Over Age 40
- Phase I/II Study Evaluating Abraxane Clinical Potential in Patients With Advanced Pancreatic Cancer Published in the Journal of Clinical Oncology Online
- Adeona's Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease is Hot Topic at 2011 California ALS Research Summit
- New Oral Drug Found to Reduce Relapses in Multiple Sclerosis atients
October 10, 2011
- Dr. Isaac Eliaz Discusses Role of Modified Citrus Pectin in Cancer Treatment at International Oncology Conference
- Mayo Clinic Study Identifies Earliest Stages of Alzheimer's Disease
- Affymax and Takeda to Present Peginesatide Data at the American Society of Nephrology Kidney Week 2011
October 11, 2011
- Study Shows That Roche?s Investigational Drug for Alzheimer?s Disease Removes Amyloid Plaques From the Brain
- Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with Copaxone
October 12, 2011
- New Study Shows Cialis Significantly Improved Study Endpoints in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia
- Dynavax Reports Positive Immunogenicity Data From an Analysis of Hypo-Responsive Populations in HEPLISAV Phase 3 Trial
- CytRx's ENABLE Phase 2 Trial Results with Bafetinib in Relapsed B-Cell Chronic Lymphocytic Leukemia to be Presented at the Prestigious 53rd Annual ASH Meeting
October 13, 2011
- Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis
- POZEN Reports Top-Line Data from Long-Term Safety Study of PA32540
- Merck's ISENTRESS (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1
- Phase 1/2 Clinical Trial Results of Perifosine Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
- The US Oncology Network-Milliman Study Shows That Evidence-Based Guidelines Could Reduce Costs in Colon Cancer Patients Receiving Chemotherapy by More Than $50,000 While Maintaining Quality Outcomes
- Scripps Research Scientists Reveal Surprising Picture of How Powerful Antibody Neutralizes HIV
- Survey of Nurse Practitioners Finds Oral Estrogen Therapy Is Prescribed More Often Than Transdermal And Examines External Influences That Affect Prescribing Practices
- KGI Professor Links MicroRNA Gene to Aggressive Skin Cancer
October 14, 2011
- Biotron Hepatitis C Phase 2a Trial Positive Results
- Women?s Heart Disease Tied to Small Blood Vessels
- Depomed Announces Top-Line Results From Serada Phase 3 Trial BREEZE 3 in Menopausal Hot Flashes
- Gut Bacteria May Affect whether a Statin Drug Lowers Cholesterol
October 16, 2011
- Hepatitis C Phase 2A Trial Positive Results
- Daval International Announces Positive Phase II Results for AIMSPRO(R) as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
- Furiex Pharmaceuticals Announces Scientific Publications for JNJ-Q2
- BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review in Phase III Program
October 17, 2011
- Novartis Drug Gilenya (fingolimod) has more than 20,000 Patient-years of Exposure and Shows up to 71% Reduction in Annualized Relapse Rates in MS Patients with Highly Active Disease
- Multi-center Clinical Trial Shows ParaPRO's Spinosad Eradicates Head Lice and Nits
- Genetic Profile Identified for Alzheimer's Patients Showing Heightened Response to Accera's Breakthrough Product Axona(R)
- Theracrine Announces Publication Identifying Potential Novel Cancer Spread Target
October 18, 2011
- The Medicines Company's MDCO-2010 Meets Clinical Trial Objectives in Patients Undergoing Open-Heart Surgery
- Roche Reports Positive Study of Herceptin Given By Subcutaneous Injection
- Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
- Pacira Pharmaceuticals, Inc. Announces EXPAREL Data to Be Presented at Upcoming Medical Meetings
- Pevion's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
October 19, 2011
- Concert Pharmaceuticals Announces CTP-499 Data Presentations at the American Society of Nephrology (ASN) Kidney Week Meeting
- Concert Pharmaceuticals Announces Data Presentations at Neuroscience 2011
- Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS
- Data about Early Use and Long-Term Benefit of Tysabri Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS
- Canadian Journal of Cardiology Publishes Report on Delayed vs. Immediate Coronary Stenting
- Genfit: A Hospital-Based Clinical Study Demonstrates the Action of Gft505 on the Liver
- New Positive Data on NX-1207 Presented at Symposium at American Urological Association Meeting October 19
- Anadys Announces Positive 12-Week Data for Setrobuvir in Phase 2b Hepatitis C Study
October 20, 2011
- Cubist to Feature Antibiotic Development Programs at 49th IDSA
- Galderma Announces Positive Phase 2b Results for Investigational Compound Targeting Redness of Rosacea
- Isentress Shown to Be More Effective in Ongoing Head-to-Head HIV Study
- Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial
- DIFICID Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
- Interim Phase IIb Data for Merck's VICTRELIS (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting
- Treatment with COPAXONE in Multiple Sclerosis Demonstrated Remyelination and Neuroprotective Effects in a Preclinical Setting
- Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
- Galderma Announces Positive US Pivotal Interim 6-Month Results for EMERVEL Classic Lidocaine Compared to Juvederm Ultra
- African American Women With Gestational Diabetes Face High Long-term Diabetes Risk
- ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day
- Tryton's Innovative Solution Highlighted at Annual European Bifurcation Club Meeting
October 21, 2011
- Boceprevir based therapy cleared the hepatitis C virus in 70 percent of patients coinfected with hepatitis C and HIV-1
- Additional Data From Pfizer's Prevnar 13 Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of America
- Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial
- Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials in Patients with Type 1 and Type 2 Diabetes
- EU Study Shows Once-Daily Lisdexamfetamine Dimesylate (LDX) Effective for Symptom Control in Children and Adolescents With ADHD
October 24, 2011
- NanoViricides' Anti-Virus Technology Published in Bionanotechnology II: Global Prospects
- NPS Pharmaceuticals Reports Upcoming Presentations at American College of Gastroenterology Annual Scientific Meeting
- Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK Combination Therapy
- Novartis Phase II Data Show AIN457 Provided Rapid and Significant Relief of Symptoms in up to 81% of Patients with Psoriasis
- New Frontier in the Treatment of Type 1 Diabetes -- Italian Researchers Present Findings in the Improvement of the Efficacy of Pancreatic Islet Transplantation
- Study Hints at Possible Therapeutic Strategy to Combat Premature Birth
October 25, 2011
October 26, 2011
- Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
- Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
- Butrans (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
October 27, 2011
- New England Journal of Medicine Publishes Additional Efficacy and Safety Data for Gardasil in Males
- Linaclotide provides long term relief from the symptoms of irritable bowel syndrome with constipation
- Full Phase III data highlight the efficacy and tolerability of Sativex as therapy for the treatment of spasticity in MS
- Interim Results Presented from Long-Term, Open-Label Extension Study Evaluating Lundbeck's ONFI (clobazam) in the Adjunctive Treatment of Drop Seizures Associated with LGS
- Favorable Clinical Trial Results for Ampion in Treatment of Osteoarthritis (AIK) Allows Testing as a Monotherapy Against "Standard of Care," Ahead of Schedule
- Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
- Chinese Study Finds No Association between BPA and Diabetes in Large Scale Clinical Trial
- Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
- Synergy Pharmaceuticals Presentations at 2011 American College of Gastroenterology Annual Scientific Meeting
- ULURU Inc. Announces Additional Data Supporting Altrazeal(R) Use in Diabetic Foot Ulcers
- Ironwood and Forest to Present Linaclotide Results from Phase 2B and Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation or Chronic Constipation
October 28, 2011
- UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting
- ZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data with Oral and IV Palifosfamide at the 2011 CTOS/MSTS Meeting
- CBIO Lupus Data Published By Oxford Journals
- Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
- VTT Identified Specific Bacteria Which Precede Autoimmune Diabetes
- Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
- Novartis Phase II data show AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
October 31, 2011
- YM BioSciences Nimotuzumab Results Reported at SIOP Conference
- Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
- Teva Presents New Data on Qnsal at the 2011 American College of Allergy, Asthma and Immunology Annual Meeting
- New Data on Cimzia (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
- InflammaGen Therapeutics to Present Case Review of InflammaGen Shok-Pak at BIO-Europe 2011
- Furiex Pharmaceuticals Study Results to be Presented at the American College of Gastroenterology 2011 Annual Scientific Meeting
- NPS Pharmaceuticals to Host Conference Call to Discuss Data Reported at American College of Gastroenterology Annual Scientific Meeting
- New Data on Cimzia (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn?s disease
- Phase 3 Gattex (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome
